Real-world evidence of suboptimal blood pressure control in patients with type 2 diabetes

被引:11
|
作者
Walraven, Iris [1 ,2 ,3 ]
Mast, M. Ruth [1 ,4 ]
Hoekstra, Trynke [1 ,2 ]
Jansen, Aaltje P. D. [1 ,5 ]
Rauh, Simone P. [1 ,2 ]
Rutters, Femke R. [1 ,2 ]
van der Heijden, Amber A. W. A. [5 ]
Elders, Petra J. M. [1 ,5 ]
Moll, Annette C. [1 ,3 ]
Polak, Bettine C. P. [1 ,3 ]
Dekker, Jacqueline M. [1 ,2 ]
Nijpels, Giel [1 ,5 ]
机构
[1] Vrije Univ Amsterdam Med Ctr, EMGO Inst Hlth & Care Res, NL-1007 MB Amsterdam, Netherlands
[2] Vrije Univ Amsterdam Med Ctr, Dept Epidemiol & Biostat, NL-1007 MB Amsterdam, Netherlands
[3] Vrije Univ Amsterdam Med Ctr, Dept Ophthalmol, NL-1007 MB Amsterdam, Netherlands
[4] Vrije Univ Amsterdam Med Ctr, Dept Clin Pharmacol & Pharm, NL-1007 MB Amsterdam, Netherlands
[5] Vrije Univ Amsterdam Med Ctr, Dept Gen Practice & Elderly Care Med, NL-1007 MB Amsterdam, Netherlands
关键词
cardiovascular mortality; hypertension; latent class growth modelling; microvascular complications; type 2 diabetes mellitus; MICROVASCULAR COMPLICATIONS; VASCULAR-DISEASE; RISK-FACTORS; MANAGEMENT; TRAJECTORIES; HYPERTENSION; MORTALITY; ASSOCIATION; RETINOPATHY; GUIDELINES;
D O I
10.1097/HJH.0000000000000680
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Aims:In order to eventually improve blood pressure (BP) management, the aim of this study was to identify subgroups of type 2 diabetes mellitus (T2DM) patients with distinct trajectories of SBP levels. Identifying subgroups with distinct SBP trajectories helps to better understand the course of SBP levels in T2DM patients and its associated consequences. Subgroup characteristics were determined and the prevalence of complications and mortality rates over time in the different subgroups was investigated.Methods:Five thousand, seven hundred and eleven T2DM patients with at least two SBP follow-up measurements were selected from a prospective T2DM cohort of 9849 T2DM patients. The mean follow-up period was 5.7 years (range 2-9 years). Latent Class Growth Modeling, as currently the most flexible cluster analysis available, was performed to identify subgroups of patients with distinct SBP trajectories. Subgroup characteristics were determined by multinomial logistic regression analyses.Results:Four subgroups with distinct SBP trajectories were identified. The largest subgroup (85.6%) showed adequate SBP control (at or around 140mmHg) over time. The second subgroup (5.6%) were hypertensive in the first years, responded slowly to BP management and eventually reached SBP control. The third subgroup (3.4%) showed deteriorating hypertension during the first 4 years, then showed insufficient response to BP management. The fourth subgroup (5.4%) showed deteriorating hypertension over time. Patients within subgroups 2-4 were significantly older, comprised more women, used more antihypertensive medication and had a higher prevalence of retinopathy, microalbuminuria and cardiovascular disease (CVD) mortality.Conclusion:More than 85% reached and maintained adequate SBP control. Subgroups with a more unfavourable course of SBP control also showed higher rates of microvascular complications and CVD mortality over time. This study identified important subgroups to target in order to improve BP management in T2DM patients.
引用
收藏
页码:2091 / 2098
页数:8
相关论文
共 50 条
  • [21] REAL-WORLD TREATMENT PATTERN IN COMMUNITY PATIENTS WITH TYPE-2 DIABETES: EVIDENCE FROM SHANGHAI, CHINA
    Gao, Y.
    Chen, L.
    Fang, H.
    Xu, D.
    Xuan, J.
    Liu, B.
    VALUE IN HEALTH, 2016, 19 (07) : A680 - A680
  • [22] Characteristics of type 2 diabetes patients with overt cardiovascular diseases in Malaysia: the real-world evidence from the National Diabetes Registry
    Kim Sui Wan
    Noran Naqiah Hairi
    Feisul Mustapha
    Muhammad Fadhli Mohd Yusoff
    Mastura Ismail
    Foong Ming Moy
    Noor Ani Ahmad
    BMC Research Notes, 18 (1)
  • [23] Real-world evidence of inhaled corticosteroids and type ii diabetes manifestation
    Albogami, Yasser
    Wei, Yu-Jung
    Daniels, Michael J.
    Cusi, Kenneth
    Winterstein, Almut G.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2020, 29 : 595 - 595
  • [24] Influence of social determinants, diabetes knowledge, health behaviors, and glycemic control in type 2 diabetes: an analysis from real-world evidence
    Silva-Tinoco, Ruben
    Cuatecontzi-Xochitiotzi, Teresa
    De la Torre-Saldana, Viridiana
    Leon-Garcia, Enrique
    Serna-Alvarado, Javier
    Orea-Tejeda, Arturo
    Castillo-Martinez, Lilia
    Gay, Juan G.
    Cantu-de-Leon, David
    Prada, Diddier
    BMC ENDOCRINE DISORDERS, 2020, 20 (01)
  • [25] Influence of social determinants, diabetes knowledge, health behaviors, and glycemic control in type 2 diabetes: an analysis from real-world evidence
    Rubén Silva-Tinoco
    Teresa Cuatecontzi-Xochitiotzi
    Viridiana De la Torre-Saldaña
    Enrique León-García
    Javier Serna-Alvarado
    Arturo Orea-Tejeda
    Lilia Castillo-Martínez
    Juan G. Gay
    David Cantú-de-León
    Diddier Prada
    BMC Endocrine Disorders, 20
  • [26] Probability of Achieving Glycemic Control with Basal Insulin in Patients with Type 2 Diabetes in Real-World Practice in the USA
    Lawrence Blonde
    Luigi Meneghini
    Xuejun Victor Peng
    Anders Boss
    Kyu Rhee
    Alka Shaunik
    Supriya Kumar
    Sidhartha Balodi
    Claire Brulle-Wohlhueter
    Rory J. McCrimmon
    Diabetes Therapy, 2018, 9 : 1347 - 1358
  • [27] A real-world analysis of glycemic control among patients with type 2 diabetes treated with canagliflozin versus dapagliflozin
    Blonde, Lawrence
    Patel, Charmi
    Bookhart, Brahim
    Pfeifer, Michael
    Chen, Yen-Wen
    Wu, Bingcao
    CURRENT MEDICAL RESEARCH AND OPINION, 2018, 34 (06) : 1143 - 1152
  • [28] Metabolic Control and Adherence to Therapy in Type 2 Diabetes Mellitus Patients Using IDegLira in a Real-World Setting
    Cheli Melzer-Cohen
    Gabriel Chodick
    Shiran Naftelberg
    Naim Shehadeh
    Avraham Karasik
    Diabetes Therapy, 2020, 11 : 185 - 196
  • [29] Switching to insulin degludec (IDeg) improves glycaemic control in patients with Type 2 diabetes in a real-world setting
    Feher, M.
    Tentolouris, N.
    Knudsen, S.
    Lapolla, A.
    Prager, R.
    Phan, T. M.
    Wolden, M. L.
    Schultes, B.
    DIABETIC MEDICINE, 2018, 35 : 203 - 203
  • [30] Metabolic Control and Adherence to Therapy in Type 2 Diabetes Mellitus Patients Using IDegLira in a Real-World Setting
    Melzer-Cohen, Cheli
    Chodick, Gabriel
    Naftelberg, Shiran
    Shehadeh, Naim
    Karasik, Avraham
    DIABETES THERAPY, 2020, 11 (01) : 185 - 196